Immunotherapy and Immunoselection -- Tumour Escape As the Final Hurdle
Overview
Authors
Affiliations
Tumours are immunogenic and are commonly infiltrated by anti-cancer effector cells. Why, then, are they not completely rejected by the host? Unfortunately, tumours are Darwinian paragons, winning the battle against the forces of natural immune selection. Some of the latter can even act as double-edged swords, actually being subverted to become pro-tumorigenic. Prevention or reversal of tumour escape from the immune response therefore offers the possibility of reconstituting effective anti-tumour immunity and remains the major challenge for 21st century tumour immunology.
CCL27 Signaling in the Tumor Microenvironment.
Martinez-Rodriguez M, Monteagudo C Adv Exp Med Biol. 2021; 1302:113-132.
PMID: 34286445 DOI: 10.1007/978-3-030-62658-7_9.
Sun Y, Yao Z, Zhao Z, Xiao H, Xia M, Zhu X Exp Ther Med. 2018; 16(2):1071-1078.
PMID: 30116358 PMC: 6090205. DOI: 10.3892/etm.2018.6342.
Predicting outcomes of prostate cancer immunotherapy by personalized mathematical models.
Kronik N, Kogan Y, Elishmereni M, Halevi-Tobias K, Vuk-Pavlovic S, Agur Z PLoS One. 2010; 5(12):e15482.
PMID: 21151630 PMC: 2999571. DOI: 10.1371/journal.pone.0015482.
Double positive CD4CD8 alphabeta T cells: a new tumor-reactive population in human melanomas.
Desfrancois J, Moreau-Aubry A, Vignard V, Godet Y, Khammari A, Dreno B PLoS One. 2010; 5(1):e8437.
PMID: 20052413 PMC: 2797605. DOI: 10.1371/journal.pone.0008437.
TGF beta secreted by B16 melanoma antagonizes cancer gene immunotherapy bystander effect.
Penafuerte C, Galipeau J Cancer Immunol Immunother. 2008; 57(8):1197-206.
PMID: 18214474 PMC: 11030049. DOI: 10.1007/s00262-008-0453-1.